康美药业股份有限公司第十届董事会2025年度第五次临时会议决议公告

Group 1 - The company held its fifth extraordinary board meeting of the tenth session on December 10, 2025, with all nine directors present, and the meeting complied with relevant laws and regulations [2][3] - The board approved the proposal to cancel the supervisory board and abolish the "Supervisory Board Meeting Rules," which will require shareholder meeting approval [3][4][60] - The board also approved multiple amendments to the company's articles of association and various internal management rules, all of which will be submitted for shareholder approval [5][6][7][8][9][10][12][14][16][18][20][22][24][26][28][30][32][34][36][38][40][42][44][46][48][50][52][54][57] Group 2 - The company plans to revise its articles of association to reflect the cancellation of the supervisory board, with the audit committee of the board taking over its responsibilities [64][66] - The total share capital of the company has been adjusted from 13,863,866,690 shares to 13,828,896,690 shares following the cancellation of 34,970,000 shares from the first and second phases of the stock incentive plan [66] - The amendments include the unification of terminology from "shareholders' meeting" to "shareholders' assembly" and the addition of provisions regarding independent directors and board committees [67][68]